AOD-9604
Also known as AOD · hGH Fragment 177-191 analog · Tyr-hGH177-191
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
AOD9604 (AD10) · Not in current stock
$40 / vial
2mg x 10 vials
AOD9604 (AD2) · Not in current stock
$20 / vial
5mg x 10 vials
AOD9604 (AD5) · Not in current stock
$25 / vial
Prices per vial · Research use only · Not medical advice.
Modified hGH fragment studied for fat metabolism without classic GH growth effects.
How to picture it
Full growth hormone is a long manual. AOD-9604 is researched as a fragment-style signal inspired by GH's fat-handling region — aimed at lipolysis-oriented messaging without opening the entire growth and IGF-1 chapter. Picture using only the fat-metabolism page of the GH book, not the whole book — body-composition research that wants selectivity over systemic growth.
Research focus & benefits
- Lipolysis-oriented GH-fragment research
- Body-composition pathway interest without full GH activity
- Selective metabolic signaling studies
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone designed to target fat metabolism while avoiding full GH receptor activity associated with growth and insulin resistance. Evidence is mixed; it remains popular in aesthetic and fat-loss peptide discussions.
Mechanism
Proposed stimulation of lipolysis and inhibition of lipogenesis via GH-fragment pathways independent of full IGF-1 axis activation.
Research uses
- Obesity drug development (historical)
- Lipolysis research
Research dosing notes
Community protocols vary; no strong approved clinical dosing standard for general fat loss.
Half-life / kinetics
Short; often multi-daily in community protocols
Common research routes
Reported considerations
- Generally mild anecdotal profile
- Injection-site irritation
- Limited long-term data
Contraindications / cautions
- Pregnancy
- Active serious illness
- Unrealistic spot-reduction expectations
Common research stacks
- CJC/IPA
- Cardio + deficit
- Fragment 176-191 (sometimes confused/compared)
Legal / access note
Not an approved obesity drug in the US; research and compounded availability vary.